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Abstract
Activating Protein 1 (AP-1) plays a vital role in cell proliferation, differentiation and apoptosis. While de-regulation of AP-1
has been linked to many cancers, little is known regarding its downstream transcriptional targets that associate with cellular
transformation. Previous studies identified PAK3, a serine/threonine kinase, as a potential AP-1 target gene. PAK3 has been
implicated in a variety of pathological disorders and over-expression of other PAK-family members has been linked to
cancer. In this study, we investigate AP-1 regulation of PAK3 expression and the role of PAK3 in cJun/AP-1-associated
cellular transformation. Our results showed elevated PAK3 expression at both the mRNA and protein level in cJun-over-
expressing Rat1a fibroblasts, as well as in transformed human fibroblasts. Elevated PAK3 expression in cJun/AP-1 over-
expressing cells associated with a significant increase in PAK3 promoter activation. This increased promoter activity was lost
when a single putative Jun binding site, which can bind AP-1 directly both in vitro and in vivo, was mutated. Further,
inhibition of PAK3 using siRNA showed a regression in the cell morphology, migratory potential and actin organisation
associated with AP-1 transformed cells. Our study is a first to describe a role for AP-1 in regulating PAK3 expression and
suggest that PAK3 is an AP-1 target required for actin organization and migration observed in transformed cells.
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Introduction
Activating Protein 1 (AP-1) regulates the expression of genes
involved in cell proliferation, differentiation and apoptosis,
regulating the cellular physiology in response to many stresses
[1;2]. Constitutive over-expression of cJun/AP-1 has been shown
to cause cellular transformation within Rat1a cells [3] and this
transformed phenotype includes changes in cell proliferation,
morphology and the induction of anchorage-independent growth
[1]. The activation of AP-1 has been linked to deregulated cell
proliferation, angiogenesis, invasion, metastasis and tumour
progression [4], and its over-expression has been observed in
breast, ovarian, endometrial, colon, cervical and lung cancers [5–
10]. Although there is substantial evidence for AP-19s role within
oncogenesis, very little is known about which of its target genes are
essential for these processes [11]. Due to the diverse role that AP-1
plays within the cell, it is thought there is a subset of its target genes
whose deregulation is vital for the maintenance of the transformed
phenotype [12]. Thus far, a limited number of genes have been
identified to play a partial role in AP-1 associated transformation;
including a hairpin-binding epidermal growth factor (HB-EGF)
[13], a scaffold protein, SSeCKS [12;14] and an extra cellular
matrix protein, SPARC [14;15]. A previous study using differen-
tial display and microarray analysis identified p21-Activated
Kinase 3 (PAK3), a member of the PAK-family of serine/
threonine kinases, to be significantly up-regulated in AP-1 over-
expressing cells [1;16].
The PAK family of proteins is divided into two subsets, Group 1
(PAK1, PAK2 and PAK3) and Group 2 (PAK4, PAK5 and PAK6)
[17]. Group 1 proteins are reported to be the primary effectors of
the small GTPases and are activated when bound by the activated
form (GTP-bound) of CDC42 and Rac1 [18]. When activated,
Group I PAK proteins have been shown to play a role in the
regulation of survival, gene transcription, signal transduction,
cytoskeletal reorganization, cell morphology and motility [17].
Originally PAK3 was thought to be predominantly expressed in
the brain, with its major function in the embryonic development of
the brain and neurons [17]. Thus, it is not surprising that there is a
strong link between PAK3 and pathological disorders such as
certain X-linked mental retardation syndromes [19] and learning
problems associated with synaptic plasticity [20]. However, over-
expression of PAK3 has been shown in thymic carcinoids,
suggesting a possible link between PAK3 and oncogenesis [21].
While there is limited reports showing PAK3 expression in
cancers, PAK1 over-expression has been linked to ovarian, breast,
bladder and lymph cancers, while elevated PAK2, PAK4 and
PAK6 expression has also been observed in prostate cancer [22].
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PAK4 is also reported to be elevated in 78% of cancer cell lines
and plays a role in focus formation [23]. PAK1 and PAK3 have
also been shown to stimulate cell migration and, through the
phosphorylation of Raf1, cause anchorage-independent growth
[24]. There is thus evidence that over-expression of the PAK
proteins associate with cancer development, however, little is
known regarding the factors that regulate their expression. The
aim of this study was to investigate the regulation of PAK3
expression by AP-1 and determine the effect of inhibiting PAK3
expression on cancer cell biology associated with AP-1 transfor-
mation. We report that cJun/AP-1 regulates elevated PAK3
expression by directly binding to the PAK3 promoter, and PAK3
expression is required for cell migration and actin organization in
transformed fibroblasts.
Results
Over-expression of cJun/AP-1 Results in Increased PAK3
Expression
Expression analysis identified PAK3 mRNA, amongst others
targets, to be up-regulated in cJun/AP-1 over-expressing cells [16].
To independently confirm PAK3 expression in response to cJun/
AP-1 induction, qRT-PCR and Western blot analysis was
performed using control rat fibroblasts, Rat1a-GFP, and a rat
fibroblast cell line with doxycycline-inducible cJun expression,
Rat1-J4. Cells were grown in anchorage-dependent (Fig. 1A & C)
and anchorage-independent (Fig. 1B, D & E) conditions and
PAK3 mRNA and protein expression levels assayed. Our results
show that PAK3 mRNA (Fig. 1A & B) and protein levels (Fig. 1C
& D) were found to be significantly elevated in response to induced
cJun/AP-1 expression in both growth conditions. The expression
of other Group 1 PAK proteins, PAK1 and PAK2, remained
relatively unchanged in response to the cJun/AP-1 induction
(Fig. 1E). Thus, the elevated PAK3 expression in response to
cJun/AP-1 induction suggests that PAK3 is an AP-1 responsive
gene.
cJun/AP-1 Activates PAK3 Promoter Activity
To investigate AP-1 regulation of PAK3 gene expression, the
(22436/+149) rat PAK3 promoter region was cloned into the
luciferase reporter vector, pGL3-Basic. Transient transfection of
the (22436/+149) rat PAK3 promoter plasmid, pGL3-Basic-
pPAK3 (22436/+149), into Rat1a-J4 cells showed a significant
increase in promoter activity in doxycycline-treated cells com-
pared to controls (Fig. 2A). This effect was not observed in Rat1a-
GFP control cells. As an alternative method of AP-1 over-
expression, transient transfection of pCMV-cJun into Rat1a
parental cells showed a significant, 2.3 fold increase in the
(22436/+149) PAK3 promoter activity (Fig. 2B). A reporter
construct containing four AP-1 binding sites, 4 X AP-1-Luc (WT),
was used as a positive control of AP-1 activity in pCMV-cJun
transfected cells. In order to identify regions within the (22436/
+149) PAK3 promoter that may be responsive to AP-1, a
bioinformatic analysis of this region, using MatInspector [25]
and ConReal [26], was done to identify potential cJun binding
sites. Several putative cJun/AP-1 TRE elements were identified
within the (22436/+149) region of the PAK3 promoter (Fig. 2C).
Deletion constructs of the PAK3 promoter, eliminating various
putative cJun binding sites, all showed increased promoter activity
in response to doxycycline-induced cJun/AP-1 expression. Inter-
estingly, the (2179/+149) PAK3 promoter construct, despite
containing only a single putative AP-1 binding site at position
(+52/+60) with the sequence of TGACGTCA, retained the
significant response to cJun/AP-1 seen in all the PAK3 promoter
constructs. This AP-1 binding site and the region surrounding it
was found to be conserved in other species, such as human, mouse
and dog, while the site itself had one nucleotide change but retains
the features of an AP-1 binding site. Site-directed mutagenesis of
this putative AP-1 binding site at (+52/+60) to ACGCGTTT
(where the underlined regions highlight the mutated bases) of the
(2179/+149) promoter construct resulted in a significant loss in
PAK3 promoter activity. This shows that the AP-1 binding site at
position (+52/+60) is necessary for the expression of the PAK3
gene in response to the doxycycline induction of cJun/AP-1.
Furthermore, to ascertain whether this increased promoter
activity, via the (+52/+60) site, seen in response to doxycycline
treatment, is directly through the presence of increased cJun/AP-
1, siRNA was used to transiently knock-down cJun protein levels.
This was done with the wildtype (+179/+149) promoter construct
in the control and doxycycline-treated cells. Inhibition of cJun did
not affect the basal activity of the uninduced (+179/+149)
promoter construct, while the knock-down of cJun affected the
increased promoter activity seen in doxycycline-induced cJun
over-expressing cells (Fig. 2D). This result provides further
evidence that cJun is required for PAK3 promoter activation.
AP-1 Binds Directly to the (+52/+60) PAK3 Promoter
Region
As PAK3 promoter deletion and mutation assays suggested that
AP-1 regulation on the PAK3 promoter occurs in the (+52/+60)
region, we used in vitro and in vivo binding assays to investigate
whether AP-1 is directly regulating PAK3 expression through
binding this region of the PAK3 promoter. An Electophoretic
Mobility Shift Assay (EMSA) was performed using a radiolabeled
double-stranded oligomer spanning the (+52/+60) region. This
in vitro binding assay showed the presence of a DNA/protein
complex when radioactively-labeled (+52/+60) oligomers of the
PAK3 promoter were incubated with protein cell lysate of Rat1a-
J4 cells treated with doxycycline (Fig. 3A, lane 1). The presence of
this DNA/protein complex was competed for with the addition of
excess unlabeled (+52/+60) oligomers (lane 2), where these added
oligomers contained the wildtype (+52/+60) sequence. The
addition of excess mutated unlabeled (+52/+60) oligomers did
not outcompete the binding of the seen DNA/protein complex
(lane 3). Supershift analysis with cJun (lane 4), JunB (lane 5) and
JunD (lane 6) antibodies suggest that the protein component of the
DNA/protein complex contains cJun and to a lesser extend JunD.
JunB was not found to play a role in the complex with the (+52/
+60) oligomer. In vivo binding of cJun to the (+52/+60) PAK3
promoter region was shown using Chromatin Immunoprecipita-
tion (ChIP) Assays, where our results show pull-down of cJun,
using a specific cJun antibody, in the presence of doxycycline-
treated Rat1a-J4 cell extracts accompanies the presence of the
(+52/+60) region of the PAK3 promoter (Fig. 3B). Together, these
results show that AP-1 is a transcriptional activator of PAK3
expression through direct binding to the (+52/+60) PAK3
promoter.
PAK3 Plays a Key Role in the Cell Morphology and
Migration Associated with AP-1-induced Transformation
Having established that PAK3 is an AP-1 responsive gene, the
functional relevance of the increased levels of PAK3 within AP-1
transformed cells was investigated. To investigate whether elevated
PAK3 is required for cJun/AP-1-induced cellular transformation,
inhibition of PAK3 using siRNA was performed. Western blot
analysis showed inhibition of PAK3 protein levels within 24 hours
of transfection with PAK3 siRNA (Fig. 4A). As cJun/AP-1
PAK3 Is an AP-1 Regulated Gene
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induction associates with changes in proliferation, morphology
and migration [1], these characteristics were investigated when
PAK3 was inhibited in a cJun/AP-1 over-expressing cells. Cell
proliferation assays in Rat1a-J4 cells, grown in the absence and
presence of doxycycline to induce cJun expression, were
performed for both anchorage-dependent (Fig. 4B) and anchor-
age-independent growth (Fig. 4C). Inhibition of PAK3 expression
using PAK3 siRNA had no effect on cell proliferation. The growth
advantage seen in cJun/AP-1 over-expressing cells grown in the
anchorage-independent condition was also not altered when
PAK3 expression was inhibited. While there was no change in
proliferation when PAK3 was inhibited, a change in the cJun-
induced cell morphology was observed. Phase contrast microscopy
showed a distinctive change in the morphology of rat fibroblasts
when cJun/AP-1 was over expressed to that of elongated, smaller
spindle-shaped cells that pack more tightly together (Fig. 4D).
When PAK3 was inhibited in cJun/AP-1 over-expressing cells, the
morphology resembled that of control cells grown in the absence
of doxycycline. Quantification of the changes in area occupied by
these cells showed that PAK3 inhibition resulted in significantly
larger cells compared to cJun/AP-1 over-expressing cells (Fig. 4D).
This illustrates that PAK3 plays a role in the altered morphology
Figure 1. Over-expression of cJun/AP-1 results in increased PAK3 expression. A & B: Real time RT-PCR analyses of PAK3 mRNA expression
in Rat1a-GFP control cells and Rat1a-J4 cells grown in the absence and presence of doxycycline. Cells were grown in anchorage-dependant (A) and
anchorage-independent (B) conditions. Results are the mean6S.E. of at least three independent experiments. (*p#0.05) C & D:Western blot analysis
showing PAK3 and cJun expression levels in anchorage-dependent (C) and anchorage-independent (D) growth conditions in Rat1a-J4 cells grown
with or without doxycycline. Bar graphs show PAK3 protein levels, relative to the b-tubulin levels for each sample,6S.E.M over three independent
experiments. (*p#0.05) E: Western blot analysis showing PAK1 and PAK2 protein levels in response to doxycycline induction in anchorage-
independently grown inducible Rat1a cells.
doi:10.1371/journal.pone.0066892.g001
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Figure 2. cJun/AP-1 over-expression causes increased PAK3 promoter activity via a binding site at position (+52/+60). The (22436/
+149) region of the PAK3 promoter, containing several putative cJun/AP- binding sites, was cloned into the pGL3-Basic reporter vector. A: Luciferase
promoter reporter assays performed in control cells, Rat1a-GFP, and Rat1a-J4 cells transiently transfected with empty vector, pGL3-Basic, and PAK3
promoter construct containing vector, pGL3-Basic-pPAK3 (22436/+149). Cells were grown in the absence and presence of doxycycline. B: Luciferase
promoter reporter assays performed in the parental rat fibroblast cell line, Rat1a, transfected with either pCMV-cJun or empty pCMV vector with the
PAK3 promoter construct containing vector, pGL3-Basic-pPAK3 (22436/+149). A plasmid containing four AP-1 binding sites, 4 X AP-1-Luc, was used
as a control showing cJun activation. C: Luciferase reporter promoter assays for deletion constructs of the PAK3 promoter region (22436/+149),
(22329/+149), (2684/+149) and (2179/+149) as well as a (2179/+149) with a mutated cJun/AP-1 binding site at position (+52/+60), in the presence
and absence of doxycycline-induced cJun/AP-1 expression. D: Luciferase reporter assays, using the (2179/+149) PAK3 promoter construct, showing
the effect of transient cJun inhibition on PAK3 promoter activity in the absence and presence of doxycycline induced cJun/AP-1 over-expression.
Results show the mean6S.E. of experiments performed in triplicate and repeated at least three times. (*p#0.05 and **p#0.01).
doi:10.1371/journal.pone.0066892.g002
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associated with cJun/AP-1 transformation as inhibiting its
expression caused a reversion in the cJun/AP-1 associated
morphology.
Changes in cell morphology are often caused by cytoskeletal
rearrangement and PAK3 has been shown to be essential for the
organization of F-actin at the leading edge of submarginal cells
[27]. We investigated whether the morphological changes
associated with PAK3 inhibition were linked to changes in actin
re-distribution. Actin staining assays were performed using
phalloidin, which binds polymeric F-actin, to investigate actin
reorganization in Rat1a-J4. Actin staining in cJun/AP-1 over-
expressing Rat1a-J4 cells revealed an increased emergence of
multiple actin-rich protrusions at the edges of the elongated,
spindle-shaped cells, compared to control Rat1a-J4 cells (Fig. 5A).
These actin-rich cellular extensions, along with the smaller
spindle-like cellular morphology, were also seen in cJun/AP-1
transformed Rat1a-J4 cells transfected with control siRNA. When
PAK3 was inhibited using siRNA in cJun/AP-1 expressing cells,
there was a change in cell shape and a reduction in cellular
protrusions. Quantification of the change in cell area occupied and
the number of cytoplasmic extensions are shown in Fig. 5B. These
results are in line with those obtained using phase contrast
microscopy. These results indicate that PAK3 plays a role in the
actin reorganization associated with cJun/AP-1 transformation.
Remodelling of the actin skeleton is known to produce the inner
motive force for the migration of cells. Thus following the changes
seen in actin reorganization of cJun/AP-1 over-expressing Rat1a-
J4 cells and the effect PAK3 inhibition had on these changes,
motility assays were performed. Transwell migration assays
showed that PAK3 inhibition reduced the migration of cJun/
AP-1 over-expressing cells (Fig. 5C). Together, these results show
PAK3 is required for cyctoskeletal organization and the migratory
potential of cJun/AP-1 transformed cells.
Figure 3. AP-1 binds directly to the PAK3 promoter at (+52/+60) both in vivo and in vitro. A: Electrophoretic Mobility Shift Assay (EMSA)
showing protein binding to the (+52/+60) PAK3 promoter region. Lane 1 shows the presence of a DNA/protein complex when the (+52/+60) PAK3
promoter radioactively-labelled oligomer was incubated with protein cell lysate of Rat1a-J4 cells treated with doxycycline. This DNA/protein complex
could be competed for with unlabelled (+52/+60) wild-type (WT) oligomers (lane 2), but not with a mutated (+52/+60) sequence oligomer (lane 3).
The second panel shows supershifted complexes using anti-cJun (lane 4), -JunB (lane 5) and –JunD (lane 6) antibodies. B: Chromatin
Immunoprecipitation Assay (ChIP) showing cJun binding to the (+52/+60) PAK3 promoter region. Rat1a-J4 cells were treated with doxycycline for
48 hrs, after which DNA and protein complexes were cross-linked and pulled down with an anti-cJun antibody. RT-PCR amplification off the pulled-
down chromatin showed cJun binding to the (+52/+60) PAK3 promoter region in the presence of doxycycline.
doi:10.1371/journal.pone.0066892.g003
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PAK3 is Necessary for the Morphology and Migration of
Transformed Human Fibroblasts
Having shown that elevated PAK3 expression in response to
cJun/AP-1 over-expression associates with some of the phenotypes
of AP-1 transformation in a rat fibroblast model system, we
investigated a possible link of PAK3 and cJun in normal human
fibroblast, WI38, and its transformed counterpart, SVWI38 cells.
PAK3 mRNA levels were found to be significantly increased in the
transformed fibroblast cells, SVWI38s, compared to the normal
Figure 4. Inhibition of PAK3 in cJun/AP-1 over-expressing cells has no effect on proliferation, but results in a change in cell
morphology. A: Western blot analysis confirming transient PAK3 inhibition using PAK3 siRNA in cJun expressing Rat1a-J4 cells. B & C: Cell
proliferation assays (MTT) in doxycycline-induced cJun/AP-1 expressing cells with or without control-A or PAK3 siRNA in anchorage-dependent (B)
and anchorage-independent (C) growth conditions. The results shown are the mean6S.E. of experiments performed in quadruplicate and repeated.
D: Phase contrast microscopy of Rat1a-J4 cells grown in the absence and presence of doxycycline with the addition of either control or PAK3 siRNA.
The bar graph shows the mean area (pixel2)6S.E. of forty cells of each condition over four fields of view quantitated with AxioVision 4.7 software.
(*p#0.05 and **p#0.01).
doi:10.1371/journal.pone.0066892.g004
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Figure 5. PAK3 inhibition affects actin organization and migration associated with cJun/AP-1 transformation. A: Fluorescent staining
of polymeric F-actin in Rat1a-J4 cells grown in the absence of doxycycline (Rat1a-J4), in the presence of doxycycline (Rat1a-J4+doxycycline), in the
presence of doxycycline with control siRNA (Rat1a-J4+doxycycline +control siRNA) and in the presence of doxycycline+PAK3 siRNA (Rat1a-
J4+doxycycline +PAK3 siRNA) using phalloidin showed cytoskeletal rearrangements. DAPI stain was used to visualize the cell nuclei. Arrows point to
cytoplasmic extensions. B: Quantitation of the changes in cell area (pixel2) (top panel) and number of cytoplasmic extensions (bottom panel) per cell
from the captured fluorescent images. Cell area was calculated using AxioVision 4.7 Software. The results show the mean6S.E. over six fields of view.
PAK3 Is an AP-1 Regulated Gene
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WI38s (Fig. 6A). Western blot analysis similarly showed increased
PAK3 protein levels in the SVWI38 cells, compared to the WI38
cells (Fig. 6B). Elevated levels of PAK3 in SVWI38 cells associate
with elevated cJun protein levels. These increased levels of cJun
appear necessary to maintain the increased level of PAK3 as cJun
knock-down in SVWI38 cells reduced the level of PAK3 protein.
PAK3 inhibition in SVWI38 transformed cells had no effect on
cell proliferation (Fig. 6C). Phase microscopy of cell morphology,
showed that inhibition of PAK3 expression in SVWI38 cells
resulted in flattened, enlarged and elongated cells, resembling the
morphology of WI38 fibroblasts (Fig. 6D). Quantification of these
results showed a significant increase in cell area in SVWI38 cells
when PAK3 is inhibited. Motility assays showed that the inhibition
of PAK3, using siRNA, in SVWI38 cells interfered with cell
migration, reducing the migration of these cells to levels of that
seen in normal WI38 cells (Fig. 6E). These results show a
distinctive role for PAK3 in the cellular transformation, specifically
within the morphological and migratory phenotype that is
associated with elevated cJun/AP-1 expression.
Discussion
Despite the deregulation of AP-1 being known to play a pivotal
role in transformation of cells and the promotion and progression
of tumourigenesis [28], very little is known about the mechanism
with which it controls its diverse down-stream functions. With such
varied targets, it is hypothesized that there is a group of AP-1
target genes responsible for inducing the transformed phenotype,
as opposed to a single effector [12]. Differential gene expression
analysis between control and cJun/AP-1 transformed cells
identified PAK3 as a potential AP-1 target gene upregulated in
response to cJun over-expression [16]. In this study, we report a
relationship between AP-1 and PAK3 and show, in a rat model
system, that over-expression of cJun results in elevated PAK3
mRNA and protein levels. In addition, we show that the PAK3
promoter is responsive to AP-1 via an interaction with the (+52/
+60) PAK3 promoter region. This study is a first to show that
cJun/AP-1 regulates the expression of a member of the Group 1
p21-Activated Kinases.
Activated cJun is highly present in many carcinomas [29;30]
and its activity is needed for Ras, a Rho GTPase, -mediated
morphological transformation [31]. PAK3, through its dynamic
interaction with Rho GTPases [24] is known to be involved in cell
morphology [17]. Our study showed that inhibition of PAK3 in
AP-1 transformed cells repressed the transformed morphology
associated with cJun/AP-1 over-expression and maintained a
morphology more closely resembling control cells, outlining a role
for PAK3 in the morphology of AP-1 transformed cells.
Although the Rho family of GTPases are thought to activate the
family of PAK proteins, it is specifically the Rho GTPases CDC42
and Rac that are the main activators of PAKs [18]. CDC42 is
thought to activate fillopodia formation, while the three isoforms
of Rac (1, 2, 3) regulate actin polymerization at the periphery of
the cell and control the development of membrane ruffles and
lamellipodia [32–34]. Though the role of PAK proteins in these
actin remodeling functions of CDC42 and Rac, PAK3, in
particular, has been shown to be essential for the organization of
F-actin at the leading edge of submarginal cells [27]. In this study
we show a role for PAK3 in the altered morphology of AP-1
transformed cells and actin reorganization underlying these
morphological changes. Our results suggest that PAK3 may be
involved in the redistribution of F-actin to form the actin-rich
protrusions on the tips of the smaller elongated AP-1 transformed
cells. Our findings support work done by Amyere et al. (2000) [35]
who show that when Rat1a fibroblasts are transformed with an
oncogene, such as K-Ras, one major or many cellular protrusions
emerge from the cells and these protrusions show active actin-rich
ruffling at the tips. On further analysis of these F-actin tips, they
showed that these ruffles were in fact curled lamelliopodia. Other
studies have also shown that the activation of PAKs lead to the
formation of lamelliopodia and motility of the cell [36–38]. This
indicates that the results seen in this study implicate PAK3,
specifically, in the cytoskeletal reorganization of F-actin in AP-1
transformed fibroblasts to result in the formation of lamelliopodia.
Remodeling of the actin in the cytoskeleton by regulatory
proteins has been shown to play a distinctive role in cancer
metastasis [39]. The Rho family of GTPases has also been shown
to be vital regulators of cell movement in response to extracellular
signals [40;41]. AP-1 activity is known to mediate motility and
invasion [42], where knock-down of AP-1 reduces directional
migration [31]. PAK1 and PAK2, the other members of the
Group 1 PAK family, are activated by cellular cues that stimulate
migration [43] with PAK1 directly initiating this movement [24].
Our results show that PAK3 inhibition in cJun/AP-1 over-
expressing cells decreases the migratory potential of these cells,
suggesting PAK3 may play a pivotal role in AP-1-associated
migration.
While the inhibition of PAK3 had a significant effect on
morphology and migration, this study showed it had no effect on
the proliferative advantage see in transformed fibroblasts and
compared to their normal counterparts (specifically within
anchorage-independent growth conditions). Although this appears
to suggest no role for PAK3 in proliferation, there is evidence to
support that PAK1, PAK2 and PAK3 can play a compensatory
role in proliferation after a loss of one of these proteins [44].
Further inhibition of PAK1 and PAK2 proteins alongside PAK3
inhibition would give a clearer understanding of the role PAK3
plays in the proliferation of AP-1 transformed cells. While PAK1,
2 and 3 may play a compensatory role in proliferation, these
proteins are not generally thought to have overlapping functions.
Interestingly, PAK3 like PAK1, has been showed to phosphorylate
Raf1 and promote anchorage-independent growth [27]. Raf has
been shown to cause transformation of polarized MDCK cells
through the activation of Rac1 [45].
In summary, our results show PAK3 is an AP-1 regulated gene
involved in maintaining the morphological and migratory
phenotype as well as a functional role for PAK3 in AP-1 associated
cellular transformation.
Materials and Methods
Cell Culture and Growth Conditions
Cells were grown in Dulbecco’s Modified Eagle’s Medium
(DMEM) with 10% heat inactivated Fetal Calf Serum (FCS)
(Gibco), 100 U/ml penicillin and 100 mg/ml streptomycin. Cells
were grown at 37uC in a 5% CO2 incubator and passaged using
0.05% trypsin and EDTA. Rat1a-J4 cells, containing a doxycy-
cline-inducible cJun construct, and Rat1a-GFP cells, containing a
doxycycline-inducible green fluorescent protein (GFP) construct,
were maintained by selection with 5 mg/ml blastacidin or induced
(**p#0.01) C: Migration assays, using transwell chambers, with doxycycline-induced cJun/AP-1 over-expressing cells with either control-A or PAK3
siRNA. The results show the mean6S.E. of experiments performed in triplicate and repeated. (*p, 0.05).
doi:10.1371/journal.pone.0066892.g005
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Figure 6. PAK3 expression is elevated in transformed SVWI38 fibroblasts and plays a role in their cell morphology and migration.
A: Real time RT-PCR for PAK3 mRNA expression levels in normal, WI38, and transformed lung fibroblasts, SVWI38. The results show the mean6S.E. of
at three independent experiments. (*p#0.05 and **p#0.01) B: Western blot analysis showing PAK3 and cJun expression in normal, WI38, and
transformed lung fibroblasts, SVWI38, as well as in SVWI38 cells with transient knock-down of cJun using siRNA. The bar graph represents the
quantitated levels of PAK3 protein relative to b-tubulin. C: Cell proliferation assays for SVWI38 cells transfected with control-A or PAK3 siRNA. The
results show the mean6S.E. of experiments performed in quadruplicate. Inset: Western blot analysis shows the transient PAK3 knock-down using
PAK3 siRNA in SVWI38 fibroblasts assayed. D: Phase contrast microscopy showing the morphology of WI38 fibroblasts compared to SVWI38
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for gene expression with 2 mg/ml doxycycline. Anchorage-
dependant growth conditions allowed cells to adhere directly to
the cell culture dish, while anchorage-independent conditions were
mimicked by plating cells onto Poly-HEME (Sigma) coated culture
dishes.
Real-time RT-PCR and Primers
RNA was extracted using 80% Trizol (Invitrogen), according to
the manufactures protocol. Complementary DNA (cDNA) first
strand synthesis was performed with ImProm-II Reverse Tran-
scriptase (Promega) and real-time RT-PCR was performed using
the StepOne Real-Time PCR System (Applied Biosystems) and
SYBR Green I mix (KAPA Biosystems), according to the
manufactures instructions. Primer sequences were as follows: Rat
PAK3 (F 59-TCACTCCTGAGCAAAGTAAACG-39; R 59-
TCCCAGAGACCAGATATCAACTT-39; 112 bp product), hu-
man PAK3 (F 59-ATGACTCTACCCACGGCAAG-39; R 59-
TACTCAGCACCAGCATCA-39; 136 bp product), rat GAPDH
(F 59-ATGACTCTACCCACGGCAAG-39; R 59-TACTCAG-
CACCAGCATCA-39; 136 bp product) and human Gus B (F 59-
CTCATTTGGAATTTTGCCGATT-39; R 59-CCAAGTGAA-
GATCCCCTTTTT A-39; 81 bp product). Gene expression of
PAK3 was standardized relative to an internal control; for rat
expression, GAPDH, and for human, Gus B. All samples were
performed in triplicate and the relative mRNA expression level of
the gene of interest was calculated using the 22DDCT method [46].
Western Blot Analysis
Protein was extracted in RIPA and separated by 10% SDS-
PAGE and transferred to a HybondTM-ECLTM nitrocellulose
membrane (Amersham Life Sciences). The membrane was
blocked in 5% low fat milk in Tris-buffered saline with 1 x
Tween and then incubated with primary antibodies: anti-PAK3
(sc-48826 (Santa Cruz)); anti-PAK1 (sc-882 (Santa Cruz)); anti-
PAK2 (sc-7117 (Santa Cruz)); anti-cJun (sc-1694 (Santa Cruz)) and
anti-b-tubulin (sc-9104 (Santa Cruz)). Primary antibodies were
detected with horseradish peroxidase-conjugated secondary anti-
bodies: anti-rabbit (#172-1019 (BioRad)) and anti-goat (sc-2020
(Santa Cruz)) and LumiGLO chemiluminescent substrate system
(KPL). ImageJ software was used to quantitate protein expression
levels, and included bar graphs represent the expression of the
each protein relative to the b-tubulin for that sample.
Promoter Analysis
Plasmid preparation. The (-2436/+149) rat PAK3 promot-
er region (GenBank Accession Number: NC_005120) was
amplified using primers: F 59-TGACGCGTAGAGAAG-
GAAGCCAAGAATC-39 (Mlu1 site in bold) and R 59-
CGCTCGAGGTGTAAGACCCCAGACAGTT-39 (Xho1 site
is underlined). PCR using high fidelity Expand Plus DNA
Polymerase (Roche) was performed on rat genomic DNA, the
products were sub-cloned into the pGEM-T Easy vector
(Promega) and excised for cloning into the luciferase reported
vector, pGL3-Basic (Promega) using Mlu1 and Xho1 restriction
enzymes. The promoter construct was verified by sequencing.
Generation of PAK3 promoter deletion
constructs. Promoter deletion constructs were made using the
included, cloned Mlu1 site and restriction enzyme sites within the
cloned promoter (EcoRI for the -2364/+149 construct; PstI for the
2684/+149 construct and NsiI for the 2179/+149 construct).
Once a region was excised out, the remaining linearized plasmid
was gel purified and the sticky ends were blunted-ended using T4
DNA Polymerase (Promega) before the plasmid was closed by self-
ligation.
Site-directed mutagenesis of the (+52/+60) putative cJun
binding site. The (+52/+60) putative cJun binding site has the
wildtype sequence of TGACGTCA. This site in the (2179/+149)
PAK3 promoter construct was mutated to ACGCGTTT (where
the underlined regions highlight the mutate bases) through site-
directed mutagenesis using the following primers: F 59-
GGTACGGTGCAGAGCCCAGGacgCGTtaTAGCATAGAA-
GAGCTAGG-39 and R 59-CCTAGCTCTTCTATGCTA-
taACGcgtCCTGGGCTCTGCACCGTACC-39 where the mu-
tated bases are in lowercase and the incorporated Mlu1 site is
underlined. After PCR amplification, Dpn1 (Promega) was used to
digest the template plasmid before the products were transformed
into JM109 highly competent cells (Promega). The introduced
novel Mlu1 restriction enzyme sites were used to confirm that
inclusion of the mutation.
Luciferase promoter assays. Promoter constructs were
transfected into rat fibroblasts using TransFectin Lipid Reagent
(BioRad). pRL-TK (Promega) was used as a control for
transfection efficiency. cJun/AP-1 expression was induced with
2 mg/ml doxycycline in Rat1a-J4 cells, and transfection with
pCMV-cJun plasmid in Rat1a cells. cJun knock-down was
performed using 20 nM cJun siRNA (sc-29223, Santa Cruz
Biotechnology) with a 3:1 ratio of TransFectin Lipid Reagent
(BioRad). Control-A siRNA (sc-37007, Santa Cruz Biotechnology)
was used as an siRNA control. Cell lysates were prepared after 48
hours using Passive Lysis Buffer (Promega) and luciferase activity
measured using the Dual-LuciferaseH Reporter Assay Kit
(Promega) and measured on the Glomax 96 Microplate lumi-
nometer (Promega).
Electrophoretic Mobility Shift Assay (EMSA)
c -32P-labled oligomers (20-mers) containing the (+52/+60)
PAK3 promoter region were incubated with crude nuclear
protein, extracted from Rat1a-J4 cells treated with 2 mg/ml
doxycycline for 48 hrs, as well as poly(dI/dC) and 56 Incubation
Buffer (100 mM HEPES (pH 7.9), 250 mM KCl, 2.5 mM DTT,
1 mM EDTA, 5 mM MgCl2, 20% Ficoll 400) after a 20 min
incubation on ice. Protein-oligomer mixtures were incubated for a
further 30 min on ice and then separated on a non-denaturing 5%
polyacrylamide gel at 150V for approximately 2 hrs at 4uC in
16TBE. For supershift analysis, anti-cJun (sc-1694 (Santa Cruz)),
anti-JunB (sc-73 (Santa Cruz)) and anti-JunD (sc-74 (Santa Curz)
antibodies were used. For oligomer competition, unlabeled (cold)
wildtype and mutant were used in 756molar excess.
Chromatin Immunoprecipitation Assay (ChIP)
Protein-DNA complexes from untreated and 48 hour doxycy-
cline-induced Rat1a-J4 cells were cross-linked with 1% formalde-
hyde and 0.125 M glycine, pH 2.5. Cells were re-suspended in
lysis buffer (1% SDS, 5 mM EDTA, 50 mM Tris-Cl, pH 8.1, 1 X
Complete Protease Inhibitor (Roche)) and sonicated to sheer
chromatin to between 400–100-bps in length. Lysates was then
fibroblasts transfected with control-A or PAK3 siRNA after 48 hours. The bar graph shows the mean area (pixel2)6S.E. of sixty cells of each condition
over six fields of view quantitated with AxioVision 4.7 software. (**p#0.01). E: Transwell motility assays measuring the number of migrating cells of
WI38 compared to SVWI38 cells transfected with control-A or PAK3 siRNA. The results show the mean -6 S.E. of the mean of experiments performed
in triplicate and repeated. (**p#0.01).
doi:10.1371/journal.pone.0066892.g006
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diluted with dilution buffer (1% Triton X-100, 2 mM EDTA,
150 mM NaCl, 20 mM Tris-Cl, pH 8.1, 1 X Complete Protease
Inhibitor) and chromatin was either immunoprecipitated with or
without anti-cJun antibody (sc-44 (Santa Cruz)) and treated with
pre-blocked protein-A agarose beads (Merck). Bead-bound com-
plexes were recovered by centrifugation and washed sequentially
with TSE I (0.1% SDS, 1% Triton X-100, 2 mM EDTA, 20 mM
Tris-Cl, pH 8.1, 150 mM NaCl), TSE II (0.1% SDS, 1% Triton
X-100, 2 mM EDTA, 20 mM Tris-Cl, pH 8.1, 500 mM NaCl),
Buffer III (0.25 M LiCl, 1% NP-40, 1% Sodium Deoxycholate,
1 mM EDTA, 10 mM Tris-Cl, pH 8.1) and TE, pH 7.4. Bound
chromatin was released from beads using elution buffer (1% SDS,
0.1 M NaHCO3) and released from formaldehyde cross-links by
heating at 65uC overnight. RT-PCR was performed on the
purified chromatin using primers spanning the (+52/+60) PAK3
promoter site (FWD: 59 AGATTGGTCCCCAGTAGCCC 39
and REV: 59 ACCCCAGACAGTTTGCGG 39).
PAK3 Transient Knock-down
Transient PAK3 knock-down was performed using 20 nM
PAK3 siRNA (bPAK sc-36182, Santa Cruz Biotechnology) with a
3:1 ratio of TransFectin Lipid Reagent (BioRad). Control-A
siRNA (sc-37007, Santa Cruz Biotechnology) was used as an
siRNA control.
Cell Proliferation Assay (MTT Assay)
MTT (3-[4,5-dimethylthiazol-2-yl]-2,5 diphenyl tetrazolium
bromide) assays were performed when transfected cells were
seeded into 96-well plates in normal growth medium with or
without doxycycline. For anchorage-independent growth, the 96-
well plates were coated with Poly-HEME prior to plating. Cell
growth was measured every 24 hours by MTT assay according to
the manufactures instructions (Roche).
Actin Staining, Microscopy and Cell Shape Analysis
Rat1a-J4 cells, plated onto coverslips in a 35 mm dish, were
transfected and treated with or without doxycycline for 48 hours.
Cells were fixed in 4% paraformaldehyde, washed twice in 0.04%
PBS-Tween and blocked in 1% BSA. Actin was labeled with
50 mg/ml Phalloidin-Tetramethylrodamine B isothiocyanate (Sig-
ma) in 15% BSA for 30 min at room temperature. DAPI was used
to stain the cell nuclei. Phase pictures were taken using a standard
fluorescence microscope, while the phalloidin images were viewed
using the Zeiss LSM 510 Meta fluorescent microscope and
captured using the ZEN 2009 camera with associated AxioVision
software (version 4.7). Human fibroblasts, WI38 and SVWI38 cells
viewed under phase contrast microscopy were photographed live
using the Motic MotiCam digital microscope. AxioVision 4.7
software was used measure changes in cell area over four or six
fields of view.
Motility Assays
12-well-plate Transwell migration chambers (Costar, Cam-
bridge MA) with an 8 mm pores were placed into lower chambers
containing 15% FCS-containing media, and cells were plated in
1% FCS-containing media in the top chamber. Migration through
the membrane was allowed for 24 hours, after which the cells on
top of the membrane were removed with a cotton swab and the
cells attached to bottom of the membrane were fixed in methanol
and stained with Crystal violet. Results were quantified using
ImageJ software.
Statistical Analysis
All experiments were performed in triplicate and were
represented as the mean6standard error of the mean. A Student’s
t-test was used to compare groups of samples and a p-value of less
than 0.05 was considered statistically significant. P-values #0.05
were marked with a (*), while p-values #0.01 were marked with
(**).
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